Drug Induced Liver Injury (DILI)
Drugs are an important reason for liver injury. Liver injury occurs because of use of more than 900 drugs, toxins, and herbs and drugs represent 20 – 40 percent of all instances of fulminant liver failure. Around 75 percent of the idiosyncratic drug reactions will leads to transplantation of liver or even death sometimes. Drug Hepatotoxicity is the most common reason for withdrawal of an approved drug. Doctors must be vigilant in recognizing drug-related liver injury as because if it will be detected earlier, then it could decrease the severity of hepatotoxicity if the drug is discontinued. The illustrations of DILI are highly variable, ranging from asymptomatic elevation of liver enzymes to fulminant liver failure. Information on commonly implicated agents and a high index of suspicion are very much essential in diagnosis.
In U.S.A., around 200 cases of acute liver failure occur every year and drugs account for over 50% of them (39% are because of acetaminophen, 13% are idiosyncratic reaction because of other meds). Drugs accounts for 2-5% of cases of patients who all are hospitalized with jaundice and around 10% of all cases of acute hepatitis.
Related Conference of Drug Induced Liver Injury (DILI)
26th International Conference on Gastroenterology and Hepatology
25th International Conference on Gastroenterology and Digestive Disorders
Drug Induced Liver Injury (DILI) Conference Speakers
Recommended Sessions
- Drug Induced Liver Injury (DILI)
- HCV/HIV Coinfection
- Hepatitis B and Other Viral Hepatitis
- Liver Cancer
- Liver Fibrosis
- Liver Growth and Repair
- Liver Imaging Modalities
- Liver Inflammation and Immunology
- Liver Transplantation and Liver Surgery (Experimental & Clinical)
- Molecular and Cellular Biology
- Other Liver Diseases
- Pediatric Hepatology
- Viral Hepatitis C
Related Journals
Are you interested in
- Advances in Medical Imaging - Gastrosummit 2027 (France)
- Celiac Disease - Gastrosummit 2027 (France)
- Colorectal Diseases - Gastrosummit 2027 (France)
- Diagnostic Biomarkers and Therapeutic Targets in Digestive Diseases - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Digestive System Cancers - Gastrosummit 2027 (France)
- Digestive System Cancers - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Endoscopy and Minimally Invasive Gastrointestinal Procedures - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Esophageal Disorders - Gastrosummit 2027 (France)
- Esophageal Disorders - Gastrosummit 2027 (France)
- Gastric Diseases and Peptic Ulcers - Gastrosummit 2027 (France)
- Gastric Diseases and Peptic Ulcers - Gastrosummit 2027 (France)
- Gastrointestinal Bleeding - Gastrosummit 2027 (France)
- Gastrointestinal Disorders and Treatment - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gastrointestinal Infections and Immunity - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gastrointestinal Oncology and Tumor Biology - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gastrointestinal Pharmacology - Gastrosummit 2027 (France)
- Gastrointestinal Surgery - Gastrosummit 2027 (France)
- Geriatric Gastroenterology - Gastrosummit 2027 (France)
- Gut Microbiota and Gastrointestinal Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Gut Microbiota and Metabolic Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Hepatology: Liver Disease and Transplantation - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Inflammatory Bowel Disease (IBD) - Gastrosummit 2027 (France)
- Inflammatory Bowel Disease and Intestinal Inflammation - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Inflammatory Bowel Diseases - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Liver and Pancreatic Disorders - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Liver Diseases and Hepatic Disorders - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Liver Diseases and Hepatology - Gastrosummit 2027 (France)
- Liver Transplantation - Gastrosummit 2027 (France)
- Non-Alcoholic Fatty Liver Disease - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Nutrition and Aging: Geriatric Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Nutrition in Digestive Health - Gastrosummit 2027 (France)
- Pancreatic Diseases - Gastrosummit 2027 (France)
- Pancreaticobiliary Disorders - Gastrosummit 2027 (France)
- Pediatric and Adolescent Nutrition - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Pediatric Gastroenterology - Gastrosummit 2027 (France)
- Pediatric Gastroenterology and Nutrition - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Peptic Ulcer and Acid-related Disorders - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Plant-Based Nutrition and Sustainable Diets - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Precision Medicine in Digestive Diseases - Gastrosummit 2027 (France)
- Role of Microbiota in Digestive Health - DIGESTIVE AND METABOLIC DISEASES 2026 (France)
- Viral Hepatitis - Gastrosummit 2027 (France)

